Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2007.14.8957 on March 17 2008

Journal of Clinical Oncology, Vol 26, No 11 (April 10), 2008: pp. 1789-1796
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Musolino, A.
Right arrow Articles by Ardizzoni, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Musolino, A.
Right arrow Articles by Ardizzoni, A.
Related Articles
Right arrowRelated Editorial

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

Antonino Musolino, Nadia Naldi, Beatrice Bortesi, Debora Pezzuolo, Marzia Capelletti, Gabriele Missale, Diletta Laccabue, Alessandro Zerbini, Roberta Camisa, Giancarlo Bisagni, Tauro Maria Neri, Andrea Ardizzoni

From the Medical Oncology Unit and Medical Genetics Unit; Laboratory of Viral Immunopathology, Department of Infectious Diseases and Hepatology, University Hospital of Parma, Parma; and the Department of Oncology, S. Maria Nuova Hospital, Reggio Emilia, Italy

Corresponding author: Antonino Musolino, MD, Medical Oncology Unit, University Hospital of Parma, via Gramsci 14, 43100 Parma, Italy; e-mail: antoninomusolino{at}hotmail.com

Purpose: The anti–HER-2/neu monoclonal antibody trastuzumab has been shown to engage both activatory (fragment C receptor [Fc{gamma}R]IIIa; Fc{gamma}RIIa) and inhibitory (Fc{gamma}RIIb) antibody receptors and Fc{gamma}R polymorphisms have been identified that may affect the antibody-dependent cell-mediated cytotoxicity (ADCC) of natural-killer cells/monocytes. In this study, we tested whether Fc{gamma}R polymorphisms are associated with clinical outcome of patients with breast cancer who received trastuzumab.

Patients and Methods: Fifty-four consecutive patients with HER-2/neu–amplified breast cancer receiving trastuzumab plus taxane for metastatic disease were evaluated for genotype for the Fc{gamma}RIIIa-158 valine(V)/phenylalanine(F), Fc{gamma}RIIa-131 histidine(H)/arginine(R), and Fc{gamma}RIIb-232 isoleucine(I)/threonine(T) polymorphisms. Trastuzumab-mediated ADCC of patients' peripheral blood mononuclear cells (PBMCs) was measured by chromium-51 release using a HER-2/neu–expressing human breast cancer cell line as a target. Controls comprised thirty-four patients treated with taxane alone.

Results: Our population was in Hardy-Weinberg equilibrium except for the Fc{gamma}RIIb polymorphism. The Fc{gamma}RIIIa-158 V/V genotype was significantly correlated with objective response rate (ORR) and progression-free survival (PFS). Also, there was trend significance in ORR and PFS for the Fc{gamma}RIIa-131 H/H genotype. The combination of the two favorable genotypes (VV and/or H/H) was independently associated with better ORR and PFS compared with the other combinations. The ADCC analysis showed that V/V and/or H/H PBMCs had a significantly higher trastuzumab-mediated cytotoxicity than PBMCs harboring different genotypes.

Conclusion: These data support for the first time the hypothesis that Fc{gamma}R-mediated ADCC plays an important role in the clinical effect of trastuzumab. Prospective studies are needed to confirm the role of Fc{gamma}R polymorphisms in predicting clinical outcome of patients with breast cancer treated with trastuzumab-based therapy.

published online ahead of print at www.jco.org on March 17, 2008.

Supported in part by the Cariparma Foundation (Fondazione Cassa di Risparmio di Parma, Parma, Italy).

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Editorial

  • The "Other" Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs
    Luca Gianni
    JCO 2008 26: 1778-1780 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
L. Gianni
The "Other" Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs
J. Clin. Oncol., April 10, 2008; 26(11): 1778 - 1780.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online